Month: April 2018

Carboplatin and BRCAness

[PMID: 29713086] [Nature Medicine]

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

“patients with advanced TNBC benefit from characterization of BRCA1/2 mutations, but not BRCA1methylation or Myriad HRD analyses, to inform choices on platinum-based chemotherapy. “

Advertisements